![project magenta price project magenta price](https://c1.neweggimages.com/ProductImageCompressAll1280/28-142-867-04.jpg)
Initial data from this trial are expected in the second half of 2021.
![project magenta price project magenta price](https://cdn.shopify.com/s/files/1/0256/7982/2882/products/Magenta_1600x.png)
Phase 2 clinical trial in collaboration with the National Marrow Donor Program®/Be The Match®, evaluating MGTA-145, in combination with plerixafor, in the mobilization and collection of stem cells from allogeneic donors for transplant in patients with Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL) and Myelodysplastic Syndromes (MDS). Preliminary results will be presented at ASCO and EHA and final clinical data from this trial are expected in the second half of 2021. This 25-patient, investigator-initiated trial will also measure engraftment and disease outcome measures, with stem cell mobilization as the primary endpoint.
![project magenta price project magenta price](https://c1.neweggimages.com/ProductImageCompressAll1280/28-651-857-01.jpg)
Phase 2 clinical trial in Multiple Myeloma is ongoing at Stanford University, evaluating the ability of MGTA-145, in combination with plerixafor, to mobilize stem cells for collection prior to autologous stem cell transplant.
![project magenta price project magenta price](https://onecms-res.cloudinary.com/image/upload/s---EqJKCcc--/f_auto%2Cq_auto/v1/mediacorp/cna/image/2021-08/bto.png)
MGTA-145 Stem Cell Mobilization and Collection Magenta will present preliminary MGTA-145 Phase 2 data in Multiple Myeloma patients at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, to be held virtually June 4-8, 2021, and at the European Hematology Association (EHA) Congress, to be held virtually June 9-17, 2021. MGTA-145 Upcoming Scientific Conference Presentations: "We are optimistic about our programs’ ability to transform clinical practice of stem cell transplants and gene therapies with new first-line medicines, which we believe could increase access to curative transplants across multiple disease areas."
PROJECT MAGENTA PRICE PLUS
"Magenta continues to make progress across our program portfolio, building momentum towards several key anticipated clinical and data milestones throughout 2021, including the initial Phase 2 trial results evaluating MGTA-145 plus plerixafor in Multiple Myeloma patients in an autologous transplant setting and filing an IND for first-in-human Phase 1/2 clinical trial of MGTA-117, our first product candidate from our targeted conditioning platform," said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta Therapeutics. The average daily energy consumption during the last 7 days has dropped to 3,579 million units from 3,864 million units in the second week of October (registering a drop of 7 per cent), whereas the peak demand also stands corrected to 168 GW from 172 GW in the second week (a drop of 2 per cent), it added.Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today reported financial results for the first quarter ended Maand recent program highlights. The onset of winters in Northern states has resulted in minimum temperature hovering around 16-degree C. This number for power plants has come down to 60 as on 27 October 21, indicating significant improvement", it said. "On 12 October 21, there were 79 power plants, which had less than 4 days of coal-stock. The coal stock at power generating stations - which was about 7.3 million tonnes on October 12 - has risen to 9.4 million tonnes as of October 27, with stock for more than 5 days, it added. Some of the reasons that have helped in the correction of power prices at the Exchange include there has been a considerable improvement in the availability of domestic coal at the power generating stations.